Examination of potential virulence factors of Candida tropicalis clinical isolates from hospitalized patients.
Candida tropicalis has been reported to be one of the Candida species which is most likely to cause bloodstream and urinary tract infections in hospitalized patients. Accordingly, the aim of this study was to characterize the virulence of C. tropicalis by assessing antifungal susceptibility and comparing the expression of several virulence factors. This study was conducted with seven isolates of C. tropicalis from urine and blood cultures and from central venous catheter. C. tropicalis ATCC 750 was used as reference strain. Yeasts adhered (2 h) to epithelial cells and silicone and 24 h biofilm biomass were determined by crystal violet staining. Pseudohyphae formation ability was determined after growth in fetal bovine serum. Enzymes production (hemolysins, proteases, phospholipases) was assessed by halo formation on agar plates. Susceptibility to antifungal agents was determined by E-test. Regarding adhesion, it can be highlighted that C. tropicalis strains adhered significantly more to epithelium than to silicone. Furthermore, all C. tropicalis strains were able to form biofilms and to express total hemolytic activity. However, protease was only produced by two isolates from urine and by the isolates from catheter and blood. Moreover, only one C. tropicalis (from catheter) was phospholipase positive. All isolates were susceptible to voriconazole, fluconazole and amphotericin B. Four strains were susceptible-dose dependent to itraconazole and one clinical isolate was found to be resistant.
IBB-Institute for Biotechnology and Bioengineering, Centre of Biological Engineering, Universidade do Minho, Campus de Gualtar, 4710-057, Braga, Portugal.
Melyssa
M
Negri
Margarida
M
Martins
Mariana
M
Henriques
Terezinha I E
TI
Svidzinski
Joana
J
Azeredo
Rosário
R
Oliveira
D000666:Amphotericin B / Q000494:pharmacology; D000935:Antifungal Agents / Q000494:pharmacology; D018441:Biofilms / Q000254:growth & development; D001769:Blood / Q000382:microbiology; D041022:Candida tropicalis / Q000187:drug effects / Q000302:isolation & purification / Q000472:pathogenicity*; D002177:Candidiasis / Q000382:microbiology*; D002404:Catheterization; D002448:Cell Adhesion; D002478:Cells, Cultured; D004798:Enzymes / Q000032:analysis; D004847:Epithelial Cells / Q000382:microbiology; D004864:Equipment and Supplies / Q000382:microbiology; D015725:Fluconazole / Q000494:pharmacology; D005656:Fungal Proteins / Q000096:biosynthesis*; D006460:Hemolysin Proteins / Q000032:analysis; D006801:Humans; D008826:Microbial Sensitivity Tests; D011743:Pyrimidines / Q000494:pharmacology; D014230:Triazoles / Q000494:pharmacology; D014556:Urine / Q000382:microbiology; D037521:Virulence Factors / Q000096:biosynthesis*; D065819:Voriconazole
D000935:Antifungal Agents; D004798:Enzymes; D005656:Fungal Proteins; D006460:Hemolysin Proteins; D011743:Pyrimidines; D014230:Triazoles; D037521:Virulence Factors; D000666:Amphotericin B; D015725:Fluconazole; D065819:Voriconazole